Literature DB >> 12407578

Use and interpretation of virological tests for hepatitis C.

Jean-Michel Pawlotsky1.   

Abstract

Four virological markers of hepatitis C virus (HCV) infection are used clinically for management of patients with hepatitis C, namely the HCV genotype, HCV RNA, HCV core antigen, and antibody to HCV (anti-HCV). The diagnosis of acute and chronic hepatitis C is based on both anti-HCV detection using enzyme immunoassays (EIA) and HCV RNA detection using a sensitive molecular biology-based technique. Other virological tools, including HCV genotype determination and HCV RNA quantification, are now used to tailor treatment to the individual patient and to determine its efficacy. This article reviews the kinetics of HCV markers during acute and chronic HCV infection, together with current assays and their practical use in the management of HCV-infected patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12407578     DOI: 10.1053/jhep.2002.36815

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  57 in total

Review 1.  Treatment of hepatitis C. The 2002 French consensus.

Authors:  D Dhumeaux; P Marcellin; E Lerebours
Journal:  Gut       Date:  2003-12       Impact factor: 23.059

Review 2.  Guidelines for stopping therapy in chronic hepatitis C.

Authors:  Mark W Russo; Michael W Fried
Journal:  Curr Gastroenterol Rep       Date:  2004-02

Review 3.  Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer.

Authors:  Harrys A Torres; Marta Davila
Journal:  Nat Rev Clin Oncol       Date:  2012-01-24       Impact factor: 66.675

4.  Improving health care and laboratory medicine: the past, present, and future of molecular diagnostics.

Authors:  Deborah M Green
Journal:  Proc (Bayl Univ Med Cent)       Date:  2005-04

5.  Hepatitis-C prevalence in an urban native-American clinic: a prospective screening study.

Authors:  Amy S Neumeister; LaVada E Pilcher; Judi M Erickson; Lora L Langley; Mary M Murphy; Nicole M Haukaas; Mark E Mailliard; Jennifer L Larsen
Journal:  J Natl Med Assoc       Date:  2007-04       Impact factor: 1.798

6.  Dynamic range of hepatitis C virus RNA quantification with the Cobas Ampliprep-Cobas Amplicor HCV Monitor v2.0 assay.

Authors:  Karine Gourlain; Alexandre Soulier; Bertrand Pellegrin; Magali Bouvier-Alias; Christophe Hézode; Françoise Darthuy; Jocelyne Rémiré; Jean-Michel Pawlotsky
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

Review 7.  Evidence-based consensus on the diagnosis, prevention and management of hepatitis C virus disease.

Authors:  Mahrukh Akbar Shaheen; Muhammad Idrees
Journal:  World J Hepatol       Date:  2015-03-27

8.  Hepatitis C virus (HCV) core antigen assay to detect ongoing HCV infection in thai injection drug users.

Authors:  Dale M Netski; Xiao-Hong Wang; Shruti H Mehta; Kenrad Nelson; David Celentano; Satawat Thongsawat; Niwat Maneekarn; Vinai Suriyanon; Jaroon Jittiwutikorn; David L Thomas; John R Ticehurst
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

9.  Significance of anti-HCV signal-to-cutoff ratio in predicting hepatitis C viremia.

Authors:  Yeon Seok Seo; Eun Suk Jung; Jeong Han Kim; Young Kul Jung; Ji Hoon Kim; Hyonggin An; Hyung Joon Yim; Jong Eun Yeon; Kwan Soo Byun; Chang Duck Kim; Ho Sang Ryu; Soon Ho Um
Journal:  Korean J Intern Med       Date:  2009-11-27       Impact factor: 3.165

10.  Prevalence and risk factors for Hepatitis C and HIV-1 infections among pregnant women in Central Brazil.

Authors:  Zelma B Costa; Gustavo C Machado; Mariza M Avelino; Clidenor Gomes Filho; Jose V Macedo Filho; Ana L Minuzzi; Marilia D Turchi; Mariane M A Stefani; Wayner Vieira de Souza; Celina Mt Martelli
Journal:  BMC Infect Dis       Date:  2009-07-27       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.